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Alterations of cell death pathways, including apoptosis and the neutrophil specific kind 
of death called NETosis, can represent a potential source of autoantigens. Defects in the 
clearance of apoptotic cells may be responsible for the initiation of systemic autoimmunity 
in several chronic inflammatory diseases, including systemic lupus erythematosus (SLE). 
Autoantigens are released mainly from secondary necrotic cells because of a defective 
clearance of apoptotic cells or an inefficient degradation of DNA-containing neutrophil 
extracellular traps (NETs). These modified autoantigens are presented by follicular den-
dritic cells to autoreactive B cells in germinal centers of secondary lymphoid organs. This 
results in the loss of self-tolerance and production of autoantibodies, a unifying feature of 
SLE. Immune complexes (IC) are formed from autoantibodies bound to uncleared cellu-
lar debris in blood or tissues. Clearance of IC by blood phagocytes, macrophages, and 
dendritic cells leads to proinflammatory cytokine secretion. In particular, plasmacytoid 
dendritic cells produce high amounts of interferon-α upon IC uptake, thereby contribut-
ing to the interferon signature of patients with SLE. The clearance of antinuclear IC via 
Fc-gamma receptors is considered a central event in amplifying inflammatory immune 
responses in SLE. Along with this, the accumulation of cell remnants represents an 
initiating event of the etiology, while the subsequent generation of autoantibodies against 
nuclear antigens (including NETs) results in the perpetuation of inflammation and tissue 
damage in patients with SLE. Here, we discuss the implications of defective clearance of 
apoptotic cells and NETs in the development of clinical manifestations in SLE.
Keywords: SLe, autoantibody, apoptosis, NeTosis, clearance
iNTRODUCTiON
Systemic lupus erythematosus (SLE) is a heterogeneous autoimmune disease associated with severe 
organ damage. SLE etiopathogenesis is a vicious cycle of autoantigen exposure, autoantibody 
production, chronic inflammation, and tissue damage. The overload of immune complexes (IC) 
containing nuclear autoantigen and the unabated production of IFN-α are hallmarks of SLE. These 
autoimmune responses are ascribed to a break in immunological tolerance. Self-tolerance is com-
promised in part by alterations of cell death pathways and/or the clearance of dead cells. Apoptosis 
and the neutrophil-specific kind of death called NETosis modify self-antigens during the cell death 
process and, if inefficient clearance is present, promote the further accessibility of these altered self-
antigens to the immune system. These are the driving forces for breaking self-tolerance, which is 
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also augmented by generation of an inflammatory milieu. Thus, 
deficiency in the clearance of various kinds of dead cells is a 
significant contributing factor for the exposure of autoantigens to 
the immune system that finally leads to autoimmune responses. 
This review summarizes implications of clearance deficiency of 
apoptotic cells and NETs in the pathogenesis of SLE.
APOPTOSiS, NeCROSiS, AND NeTosis
In 2012, the Nomenclature Committee on Cell death (NCID) sug-
gested cell death be divided as programed, regulated, and acciden-
tal. Programed refers to those physiological kinds of cell death that 
occur during the developmental phase of the embryo and tissue 
homeostasis (1). Apoptosis is a type of programed cell death occur-
ring during development and aging and helps to maintain tissue 
homeostasis. The term apoptosis was first coined by Kerr et al. to 
describe cell death with specific morphological features, including 
cell shrinkage (pyknosis), cytoskeleton remodeling, chromatin 
condensation, nuclear fragmentation (karyorrhexis), structural 
changes in cytoplasmic organelles, and plasma membrane blebbing 
(2–4). Various stimuli of physiological or pathogenic nature may 
trigger apoptosis via extrinsic death receptor pathways or intrinsic 
mitochondrial pathways (5). Apoptotic cells are immediately 
phagocytosed by phagocytes and degraded within the phagolys-
osomes. Apoptosis is usually an immunologically silent process (6). 
This feature of apoptosis is warranted since apoptotic cells expose 
the phospholipid phosphatidylserine (PS) (7) while maintaining 
their plasma membrane integrity, thus preventing release of cellular 
constituents into the surrounding interstitial tissue (8).
Necrosis is defined as the state of a cell that has suffered 
accidental or intentional death. Extreme harsh physical condi-
tions may trigger accidental cell death. These conditions cannot 
be inhibited by pharmacological and/or genetic manipulations 
(1). Necrosis is morphologically characterized by an increase in 
cell volume (oncosis), swelling of organelles, rupture of plasma 
membrane, and release of damage-associated molecular pat-
terns (DAMPs) into the extracellular space (9). Necrosis may 
also occur at the end of an ongoing apoptotic process in the 
absence of sufficient clearance and is named secondary necrosis. 
DAMPs are usually invisible to the immune system since they 
are confined to the intracellular space of living cells. ATP, uric 
acid, the high-mobility group box-1 protein HMGB-1, and heat 
shock proteins are the best characterized DAMPs, and they may 
act as chemoattractants or directly stimulate the immune system 
once released (10). These molecules determine the outcomes of 
cell death for the living organism. For example, ATP is a potent 
chemoattractant and when released with other proinflammatory 
DAMPs initiate inflammation and immunity (11).
NETosis is a special form of death executed by neutrophils, in 
which nuclear chromatin, histones, and granular antimicrobial 
proteins are extruded from the cell forming neutrophil extracel-
lular traps (NETs). NETs are thought to play a role in trapping 
pathogens, such as bacteria, fungi, viruses, and parasites, pre-
venting dissemination and killing microbes by the inactivation 
of virulence factors. NETosis is physiological cell death induced 
by stimuli, such as pathogens and reactive oxygen species (ROS). 
In addition, IFN-α, MSU crystals, IL-8, IL-1β, platelet-activating 
factor (PAF), and TNF-α can induce NETs (12). NETosis result 
from a series of molecular events, which include (a) NADPH oxi-
dase, superoxide dismutase, myeloperoxidase (MPO)-mediated 
superoxide, and ROS generation, (b) translocation of neutrophil 
elastase (NE) and MPO from granules to the nucleus, (c) process-
ing of chromatin, and finally (d) rupture of plasma membrane. 
Compared to apoptosis, NETosis is less well coordinated but 
requires specific molecular events, such as ROS production 
and peptidylarginine deiminase (PAD4)-mediated chromatin 
citrullination. NETosis is a kind of regulated cell death since 
recent research has identified several different ways of executing 
NETosis. Moreover, knocking out important genes for NETosis 
does not render neutrophils incapable of DNA externalization, 
although usually does lower efficacy/efficiency of this process 
(13). Other cell types, such as eosinophils and mast cells, can also 
die by this mechanism; thus, ETosis is the general name referring 
to death with release of extracellular traps (14).
CLeARANCe OF APOPTOTiC CeLLS
As part of the normal process of tissue homeostasis in higher 
organisms, billions of cells die everyday. During development, 
many extra cells are generated and die. Cells also die due to 
microbial and viral infections and mechanical injuries. To 
prevent the accumulation of aged, superfluous, infected, dam-
aged and dead cells, and debris, they are rapidly and efficiently 
cleared by professional phagocytes in an immunologically silent 
manner (3) This clearance process starts when the apoptotic cell 
secretes “find-me” signals, such as ATP, UTP (15), sphingosine-
1-phosphate (S1P) (16), lysophosphatidylcholine (LPC) (17), 
and fractalkine (CX3CL1) (18), which stimulate migration 
and activation of leukocytes toward the dying cells (19). To 
prevent inflammation, migration of neutrophils toward dying 
cells is inhibited by secretion of lactoferrin (LF), which acts 
like a “keep-out” signal (20). Then, dying cells display “eat-me” 
signals to facilitate recognition and engulfment. PS is the best 
known eat-me signal, and it is exposed on the outer leaflet of the 
plasma membrane lipid bilayer during early stages of apoptosis. 
PS has been reported to be expressed on viable, apoptotic, and 
necrotic cells. However, the lateral mobility and density of PS 
residues can be differently exposed by some viable cells, thus 
indicating a “don’t-eat-me” signal (21, 22). Apoptotic cells are 
recognized directly by phagocytes through PS receptors, such 
as Tim-4, Tim-1, Bai-1, and Stabilin-2 (3). Exposure of PS on 
apoptotic cells can also be recognized indirectly by phagocytes 
with the help of several bridging molecules, such as the Milk fat 
globule EGF factor 8 (MFG-E8), the C-reactive protein (CRP), 
or growth arrest-specific 6 (Gas-6) (23, 24). The engulfment of 
apoptotic cells by phagocytes proceeds through rearrangement 
of actin cytoskeleton to form the phagosome and transfer of dead 
cell cargo to lysosomes in a process called phagosome matura-
tion (25). The molecular pathways involved in this process are 
partially known and have been reviewed elsewhere (26).
The uptake of apoptotic cells by phagocytes is followed by 
the secretion of “tolerate me” cytokines, such as transforming 
FiGURe 1 | evidence for a clearance deficiency in the etiology of SLe. In normal healthy donors (NHD), apoptotic cells are efficiently cleared by macrophages 
and opsonins, avoiding the exposure of autoantigens and promoting tolerance. In patients with SLE, impaired clearance of dead and dying cells due to less efficient 
macrophages, deficiency of opsonins, and presence of anti-opsonin antibodies leads to autoantigen exposure through secondary necrotic cells (SNECs) formation. 
Accumulation of SNECs in germinal centers facilitates autoantigen presentation by follicular dendritic cells to autoreactive B cells. In consequence, the 
immunological tolerance is compromised and the autoimmune response is initiated.
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growth factor β (TGF-β) and interleukin-10 (IL-10), which 
further inhibit recruitment of macrophages at the site of dying 
cells and decrease secretion of proinflammatory cytokines, such 
as TNFα, IL-1, and IL-12. In summary, the clearance of apoptotic 
cells actively creates an anti-inflammatory milieu at sites of bona 
fide apoptotic cell death (27).
eviDeNCeS OF iMPAiReD CLeARANCe 
OF APOPTOTiC CeLLS iN SLe
Svensson et  al. described for first time that macrophages from 
about 50% of patients with SLE showed an impaired phagocytic 
activity for yeast (28). Monocyte-derived macrophages (MoMa) 
from patients with SLE are reportedly smaller than that of normal 
healthy donor. In vitro-differentiated macrophages from SLE 
patients were shown to have a decreased and delayed engulfment 
capacity for autologous apoptotic material (29, 30). CD34-
positive hematopoietic stem cells from peripheral blood of SLE 
patients also showed reduced differentiation to macrophages (31). 
Moreover, macrophages from SLE patients have reduced adher-
ence and had lower phagocytic activity (32); SLE phagocytes have 
significantly lower expression of the cell adhesion receptor CD44, 
which is involved in clearance processes (33).
The clearance of apoptotic cells in vivo was investigated in lymph 
node biopsies. In control specimens, apoptotic lymphocytes are 
efficiently removed by tingible body macrophages (TBMs). These 
cells are located in the unique microenvironment of the germinal 
centers in close proximity to follicular dendritic cells (FDC) (34). 
The autoimmune response in patients with SLE shows attributes 
of an antigen-driven T cell-dependent immune response, which 
actually takes place in the germinal centers of secondary lym-
phoid organs (35, 36). The amount of TBMs found in germinal 
centers of several patients with SLE appears to be reduced (37). 
Although FDC do not express class II MHC molecules, they retain 
antigens on their surfaces and can induce costimulation with the 
help of pattern-recognition receptors. In the healthy situation, 
apoptotic remnants are not accumulated in the germinal centers, 
which otherwise would be a potential source of autoantigens. 
Normally, autoreactive B cells can emerge by chance during the 
process of somatic hypermutation, but these cells never receive 
help since nuclear autoantigens are absent. Consequently, they 
die by apoptosis. In contrast, in several patients suffering from 
SLE, a clearance deficiency leads to the accumulation of nuclear 
material and/or modified autoantigens on FDC of germinal cent-
ers (37). In this scenario, stochastically generated autoreactive B 
cells leave the cell cycle and encounter autoreactive follicular B 
helper T cells (TFH) (38, 39). This fosters the formation of auto-
reactive long-lived plasma cells and consequently the initiation 
of autoimmunity (Figure 1). Anti-dsDNA, anti-histone, anti-Sm, 
anti-SS-B/La, anti-ribosomal (Ro), and anti-ribonucleoprotein 
(U1RNP) are examples of antinuclear autoantibodies (ANA) 
frequently found in patients with autoimmune manifestations 
(40). Similarly, antiphospholipid and anti-C1q autoantibodies 
TABLe 1 | Autoantibodies generated due to clearance deficiency in 
patients with SLe and associated organ affection.
Apoptosis (40, 43, 44)






Neonatal lupus syndrome (48), congenital 
heart block (48), dermatitis (49)










Anti-catalase Enhanced lipid peroxidation (56), high disease 
activity (57)
Anti-cathelicidin/LL37 No association with disease  
manifestations (58)
Anti-C1q LN (53)
Anti-cathepsin G LN (59)
Anti-proteinase 3 Serositis (60), periodontitis (61)
Anti-lactoferrin LN, skin manifestations, and serositis (62, 63)
Anti-myeloperoxidase LN (63, 64)
APS, antiphospholipid syndrome; LN, lupus nephritis; NPSLE, neuropsychiatric 
systemic lupus erythematosus; RNP, ribonucleoprotein.
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are associated with SLE (41). The presence of non-cleared cell 
remnants in sites where immune tolerance is maintained and the 
detection of autoantibodies directed against cell remnants consti-
tutes the body of evidence that autoimmunity in SLE is triggered 
by an impaired clearance of dead and dying cells. Once these 
ANA deposit in tissues and form IC, they activate complement 
and induce inflammation, vascular damage, thrombosis, or brain 
damage (Table 1). Therefore, they have the potential to be used 
as biomarkers of the different clinical manifestations of SLE (42).
Several murine models of lupus fail to reproduce all clinical 
and serological manifestations of human SLE; in particular, the 
IFN signature is missing in many approaches of targeted dele-
tion for specific immune regulator genes. Only the injection of 
the isoprenoid alkane pristane in B6 or BALB/c strains causes 
a lupus-like systemic syndrome with autoantibody produc-
tion, nephritis, arthritis, serositis, alveolar hemorrhages, and a 
strong interferon signature (65). These manifestations are most 
probably caused by the accumulation of dead cells in several 
organs of the treated animals (66). This supports the idea of an 
overload of the clearance capabilities in these mice, breakdown 
of tolerance, IC-deposition, and organ damage as believed for 
human SLE.
Toll-like receptor (TLR) activation induced by redundant 
nuclear autoantigens is considered as one important factor for 
autoantibody production in several mouse models (67–69). 
Therefore, targeting genes involved in the clearance of apoptotic 
cells may result in phenotypes closer resembling human SLE. 
The tyrosine kinase c-Mer and the Milk fat globule protein factor 
8, which recognize apoptotic cells through Gas6 and integrin 
receptors (70, 71), respectively, are involved in the recognition 
and engulfment of early apoptotic cells. Mice deficient for these 
proteins display defective phagocytosis of apoptotic cells and, 
over time, develop autoantibodies against DNA and chromatin 
(72, 73). Extracellular chromatin is cleared very efficiently by 
endonucleases such as DNase 1. Loss of function of DNase 1 
gene or its lower expression has been found in affected kidneys 
of lupus prone mice (74). The action of the intracellular DNase II 
expressed in the macrophages of the reticuloendothelial system is 
extremely important for the prevention of autotoxicity mediated 
by type I IFN (75). Furthermore, if DNase II is deleted and the 
consequent type I IFN response is suppressed by the additional 
deletion of the INF-IR gene, the mice develop chronic polyarthri-
tis resembling human rheumatoid arthritis (RA). This is because 
of their inability to digest engulfed nuclei from erythroid precur-
sors during erythropoiesis (76).
NeUTROPHiLS iN SLe
Neutrophils are short-lived and the most abundant effector 
cells of the innate immune system. They rapidly accumulate at 
sites of tissue injury, in the presence or absence of infection, 
and prevent further invasion of bacteria and fungi. Additionally, 
neutrophils are involved in other immune functions, such as 
phagocytosis, cytokine secretion, production of antimicrobial 
agents, and NETs and are potent stimulators of adaptive immu-
nity. In 2004, a specialized form of neutrophil cell death was 
described as NETosis. Since this discovery, NETs are considered 
as a potential source of autoantigens in autoimmune diseases. 
The deficiency of NET clearance has been correlated with high 
titers of anti-NET antibodies and renal involvement in patients 
with SLE (77).
Neutrophils from patients with SLE showed various abnormali-
ties in their phenotype and function. Peripheral blood of patients 
with SLE showed an increased amount of circulating apoptotic 
neutrophils, which also correlate with disease activity and may 
provide excess autoantigen including dsDNA (78). We have 
investigated neutrophil phagocytic function in healthy donors 
and patients with SLE. Most of the neutrophils from patients with 
SLE showed impaired phagocytosis of albumin-coated beads and 
about 30% had impaired ability to phagocytose Ig-coated beads. 
Phagocytosis of necrotic cells and degraded chromatin by PMN 
was also reduced in some SLE patients (30), but more convincing 
evidence for the role of neutrophils is an increase in various NET 
proteins, such as defensins, high-mobility group box protein 1 
(HMGB1), and bactericidal proteins in lupus blood compared to 
healthy donor blood (79, 80).
In SLE, prevalence of antineutrophil cytoplasmic antibodies 
(ANCA) has been reported and target antigens for ANCA are 
lysosomal proteins, proteinase 3, MPO, LF, elastase, and cath-
epsin G (81). There are conflicting reports on an association 
between the presence of ANCA and SLE. Some reports showed 
similar clinical features and antibody profile in ANCA-positive 
and ANCA-negative SLE patients (82, 83). Fauzi et al. reported 
no association of ANCA with disease activity and organ 
involvement (82). However, Tamiya et al. reported significantly 
higher values of defensin and cathepsin G-ANCA in active 
SLE patients than inactive SLE patients, suggesting the role of 
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ANCA in disease activity of SLE (84). Several studies have also 
reported that the titers of ANCA were higher in lupus nephritis 
(LN) patients compared to SLE patients without nephritis (63, 
85, 86). Hence, ANCA in SLE might be useful as serological 
marker to differentiate LN from SLE without nephritis. ANCA 
in SLE are also associated with nervous system disorder, 
myocarditis, renal involvement, serositis, and several other 
autoantibodies (86). Although a precise pathogenic role for 
ANCA in SLE is still elusive, it may serve as a useful marker of 
disease activity in SLE.
In 1986, the presence of low buoyant density granulocytes 
(LDG) in peripheral blood mononuclear cell (PBMC) prepara-
tions from patients with SLE was first reported (87). It was shown 
that humoral components of plasma from these patients were 
responsible for this phenotype. The presence of LDG in SLE blood 
was further confirmed by the abundance of neutrophil-specific 
genes in PBMC microarray. Functional studies of LDG revealed 
their proinflammatory and IFN-synthesizing capability (88). 
LDG gene profile comparison with normal density neutrophils 
from patients with SLE and control neutrophils revealed LDG are 
more prone to synthesize NETs and increased externalization of 
the bactericidal protein LL-37, IL-17, and autoantigens. Since it 
has been shown that neutrophils from patients with high titers of 
autoantibodies readily uptake DNA-containing IC in the circula-
tion (89), we suggest that neutrophils having ingested this kind of 
nuclear-IC might be responsible for the generation of LDG and 
therefore an important part of the pathogenesis of SLE. Further 
investigations are needed to address this.
NETosis is induced by the proinflammatory cytokines 
IL-17A, TNF-α, IL-8, and IL-1β in RA, gout (90, 91), and 
SLE (92). IFN-α is an important driving force for priming 
neutrophils to execute NETosis (93) and since IFN-α signature 
is a hallmark of SLE, NETs may be considered as part of the 
etiopathogenesis of SLE. It has also been demonstrated that 
neutrophils from patients with SLE produce IFN-α in response 
to circulating chromatin. This kind of neutrophil priming may 
lead to an increased NETosis (94) (Figure 2).
CLeARANCe DeFiCieNCY OF NeTs  
iN SLe
In normal conditions, MoMa efficiently clear NETs, and this 
process is facilitated by the extracellular preprocessing of NETs 
by DNase I and C1q (95). The cooperation of DNase I and C1q in 
degrading chromatin has also been reported previously (96). After 
ingestion by macrophages, NETs are shuttled via phagosomes to 
lysosomes to be degraded. The uptake of NETs by macrophages 
does not induce proinflammatory cytokine secretion and is 
therefore immunologically silent (95).
Yeh et  al. showed that 62% of sera from SLE patients were 
positive for anti-DNase antibodies compared to only 8% of 
healthy controls. They also found positive correlation between 
anti-DNase and anti-DNA antibodies in sera of SLE patients. 
Antibodies recognizing a conserved epitope near the catalytic site 
of DNase protect NETs from degradation and may therefore par-
ticipate in the pathogenesis of SLE (97). Two independent studies 
have confirmed that NETs are not efficiently degraded by sera 
from a subpopulation of SLE patients, while healthy donor serum 
efficiently supported NET degradation. Hakkim et  al. reported 
that serum DNase I is required to degrade NETs. They identi-
fied two subpopulations in SLE sera, 63.9% were degraders and 
36.1% were non-degraders. Sera from these non-degraders was 
further divided as group 1, which showed digestion of NETs by 
the addition of nuclease indicating presence of DNase I inhibitor 
in SLE sera. Group 2 were unable to degrade NETs with MNase 
showing presence of anti-NET antibodies that protect NETs from 
DNase action. They also showed the deposition of antibodies on 
NETs in renal biopsy of “non-degraders” indicating deposition 
of IC within the kidneys, causing LN (77). Impaired NET deg-
radation in SLE patients was further confirmed by Leffler et al. 
(98). Interestingly, they observed a decreased ability of serum to 
degrade NETs in active SLE patients. They also showed that C1q 
binds to NETs and prevents degradation by DNase I. Decreased 
NET degradation and increased complement activation were 
related to the presence of NET-specific autoantibodies. These 
studies concluded that the decreased ability to degrade NETs is a 
common feature of SLE (Figure 2).
In analogy to the deficient clearance of apoptotic cells, the 
inefficient degradation of NETs can also be involved in the gen-
eration of autoantibodies. This idea is supported by the presence 
in some patients with SLE of antibodies against chromatin and 
neutrophil proteins, such as MPO, proteinase-3, LF, and elastase 
(77). Schorn et  al. have investigated the opsonization of NETs, 
which may foster an FcR-dependent clearance. Since canonical 
dead cell opsonins C3b, CRP, and galectin 9 did not bind to 
MSU-induced NETs, they propose NETs as problematic prey for 
the normal opsonin-mediated clearance and a potential antigenic 
structure for etiopathogenesis of systemic autoimmunity (99).
Taken together, all this evidence suggests that NETs may 
serve as a source of autoantigens that induce the production of 
anti-NET antibodies. The involvement of an impaired clearance 
of NETs and NET-derived material in the pathogenesis of SLE is 
an emerging aspect of SLE research, and NETs might represent a 
novel diagnostic and therapeutic target.
OPSONiNS iN SLe
The clearance of dead and dying cells not only depends upon 
functioning phagocytes but also upon soluble proteins that act 
as opsonins and/or bridging molecules. Engulfment of apoptotic 
cells is enhanced by opsonizing proteins, such as C-reactive 
protein (CRP), serum amyloid P component (SAP), C1q, IgM, 
and MBL, among others, and constitute a redundant back-up 
mechanism.
Natural IgM, along with C1q, facilitates engulfment of dead 
cells by macrophages. Quartier et al. showed phagocytic activity 
of macrophages is reduced threefold to fourfold in the absence of 
IgM (100). It has been postulated that a reduced level of natural 
IgM in SLE may lead to inefficient clearance of apoptotic cells, 
which can result in the accumulation of dying cells in periph-
eral blood of these patients (101). Biermann et al. summarized 
evidence for the role of natural IgM in facilitating clearance of 
FiGURe 2 | Model of the pathogenesis of SLe. Impaired clearance of apoptotic cells and NETs is the main contributing factor in the etiopathogenesis of SLE. 
Inefficient clearance of apoptotic cells leads to the accumulation of secondary necrotic cells (SNECs), along with the release of proinflammatory cytokines by 
pathologically activated phagocytes. Circulating SNECs are sensitized by autoantibodies. This results in tissues deposition of immune complexes (IC). IC are then 
cleared by blood-borne phagocytes, such as macrophages and dendritic cells, which consequently release IFN-α and other inflammatory cytokines. The unabated 
production of IFN-α precipitates cell death and organ damage. Uncleared NETs serve as a source of autoantigen and initiate antineutrophil cytoplasmic antibodies. 
Internalization of antineutrophil cytoplasmic antibody (ANCA) immune complexes by pDCs causes an enhanced release of IFN-α. Increased IFN-α levels prime 
neutrophils to undergo NETosis. The presence of DNase-inhibitors, anti-dsDNA autoantibodies, and low levels of opsonins in patients with SLE worsen the 
clearance of NETs. A vicious cycle is initiated leading to the formation and deposition of more IC, inflammation, cell death, and organ damage. Abbreviations: ANCA, 
antineutrophil cytoplasmic antibody; IC, immune complex(es); SLE, systemic lupus erythematosus; SNEC, secondary necrotic cell-derived material; NETs, neutrophil 
extracellular traps; Ag, antigen.
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apoptotic cells by binding to autoantigens and further preventing 
inflammatory responses (24).
A genetic defect in any of the early complement proteins of 
the classical complement pathway is associated with a high risk 
(>80%) of developing SLE (102). The first complement of the 
classical pathway, C1q, is a strong opsonin for phagocytosis of 
late apoptotic and necrotic cells. C1q was found to be essential 
for effective uptake of degraded chromatin by monocyte-derived 
phagocytes (96). Gaipl et al. concluded that additional protection 
from chromatin, implicated in the development of autoim-
mune disorders such as SLE, can be achieved by the C1q- and 
DNase I-dependent degradation of chromatin (103). However, 
the majority of SLE patients develop an acquired deficiency of 
complement proteins due to their consumption as the disease 
progresses, causing inflammation and tissue damage (102). 
Genetic deficiency of complement proteins C2 and C4 are rare 
but also associated with SLE, glomerulonephritis, and infections 
(104, 105). The frequency of anti-RO antibodies was significantly 
higher in complement deficient SLE patients than those without 
hereditary complement deficiencies (105). Complement compo-
nents are involved in the clearance of IC. It has been reported that 
C4-deficient mice had a delay in clearance of circulating IC (106). 
This delay could result in accumulation of IC and may further 
lead to inflammatory damage in organs, such as kidneys.
C-reactive protein, SAP, and the long Pentraxin 3 (PTX3) bind 
apoptotic material. This results in the amplification of the classical 
pathway of complement activation. This increases phagocytosis 
of dead and dying cells with a subsequent anti-inflammatory 
response. Mattecka et al. studied binding of CRP and SAP from 
different species to ligands that are commonly exposed during 
cell death. They observed that human CRP and SAP bind to 
phosphatidylethanolamine and LPC, respectively (107). CRP is a 
positive acute phase protein, meaning its concentration increases 
profoundly during inflammation. CRP binds to damaged cell 
membranes and nuclear components, such as U1 snRNP and 
histones (108, 109), that are targets for autoantibodies in SLE 
serum. Janko et al. showed that the binding of CRP to necrotic 
PBMCs increased with DNase treatment, indicating CRP binds 
to non-DNA epitopes of necrotic cells. The low levels and activi-
ties of CRP and DNase I found in SLE blood leads to reduced 
opsonization of dead cells by CRP. This contributes to the 
accumulation of dying and dead cells in SLE (110, 111). Hence, 
binding of this opsonin to nuclear components and ligands on 
dying cells sequesters auto-epitopes, which otherwise could elicit 
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autoimmune responses. Low levels of CRP in SLE might occur 
due to consumption of serum CRP by postapoptotic cells, which 
are not cleared because of clearance deficiency. In a human, 
CRP gene polymorphism study in patients with SLE, CRP2, and 
CRP4 haplotypes associated with low CRP levels. CRP4 was also 
associated with ANA and development of SLE (112). Reduced 
basal levels of CRP have been associated with autoimmunity, 
particularly with ANA production, and with SLE. Sjowall et al. 
confirmed the high prevalence of anti-CRP autoantibodies in 
SLE. They report that the levels of these correlate with clinical 
and laboratory disease activity measures (113). Moreover, it has 
been demonstrated that IFN-α has an inhibitory effect on CRP 
secretion. This has provided an additional explanation for the low 
CRP levels during SLE flares (114).
Serum amyloid P component displaces H1-core histones, 
thereby solubilizing chromatin fragments from necrotic cells 
(115). High titers of autoantibody to SAP have been detected in 
22–69% of blood samples from patients with SLE; the titers cor-
related with disease activity and decreased with improvement of 
clinical disease (116). PTX3 binds to late apoptotic cells and cell 
debris, and anti-PTX3 autoantibodies are found in patients with 
SLE (27). Deficiency of complement components and pentraxins 
leads to impaired clearance, which causes the accumulation of 
secondary necrotic cells, inducing maturation of dendritic cells. 
Mature dendritic cells can present self-antigens that may lead to 
the loss of T cell tolerance and the induction of autoimmunity 
(27). The presence of autoantibodies against these opsonins 
fosters the Fc-receptor-mediated engulfment of SNEC material, 
fueling consequent inflammation in patients with SLE (110).
SeNSiBiLiZATiON OF SNeC AND 
UNCLeAReD NeTs BY AUTOANTiBODieS
Accumulation of late apoptotic cells and NETs provides natural 
sources of autoantigens. In the model of the etiopathogenesis of 
SLE, an inefficient clearance of apoptotic cells and NETs, together 
with a susceptible genetic background, initiates the autoimmune 
response. In patients with SLE, autoantigens are targeted in 
apoptotic blebs during the execution phase of apoptosis (117). 
A clearance deficiency will also facilitate the exposure of modi-
fied autoantigens (SNECs) to already generated autoantibodies 
(27). SNECs are exposed during apoptosis and subject to caspase 
cleavage and other post-translational modifications, such as 
phosphorylation, dephosphorylation, ubiquitination, acetylation, 
and citrullination, and this may increase their immunogenicity 
(92). The binding of autoantibodies to persistently circulating 
SNEC in SLE patients’ blood leads to the formation of IC. It has 
been shown that autoantibodies in SLE sera often enhance the 
phagocytosis by blood-borne phagocytes and tissue macrophages 
of apoptotic (118) or necrotic cells (119). Anionic phospholipids, 
particularly PS, are generally concentrated at the surface of 
apoptotic blebs. PS-binding proteins, such as β2 glycoprotein 
and annexin V, decorate apoptotic cells. IgG from SLE patients 
with antiphospholipid syndrome also binds to these proteins on 
non-cleared late apoptotic cells, enhancing immunogenicity by 
the concurrent secretion of TNF-α (41).
Sensibilization of SNEC, either with anti-SNEC or with anti-
opsonin antibodies, shifts the clearance of SNEC toward inflam-
mation by engaging Fc receptors and complement components. 
Interestingly, supplementation of healthy donor blood with IgG 
from SLE patients enhances ingestion of SNEC by phagocytes from 
the healthy donors. SNECs have binding sites for opsonins and 
anti-opsonin antibodies that are frequently found in SLE blood. 
The uptake of IgG-sensitized SNEC is tightly coupled with the 
secretion of high amounts of various proinflammatory cytokines, 
such as IL-8, IL-1β, TNF-β, IL18, and IFN-α (Figure 2) (89, 110).
Uncleared NETs also serve as source of autoantigen. NET 
proteins, such as LL37, histones, dsDNA, neutrophil defensin, 
catalase, and annexin A1, are considered autoantigens in SLE 
(120). It has been described that NETs with modified histones 
are not properly cleared in patients with SLE. DNase gene 
polymorphisms as well as inhibitory anti-DNase I antibodies 
may contribute to this phenotype. NET-bound proteins, such as 
HMGB1, LL37, C1q, and anti-chromatin autoantibodies, may 
prevent the access of DNase I to the NETs (92). Therefore, like 
uncleared apoptotic cell remnants, uncleared NETs contribute 
to an increase in the exposure of modified autoantigens to the 
immune system (Figure 2).
iFN-α SiGNATURe OF SLe
IFN-α is produced by many cells in response to viral infections. 
Plasmacytoid dendritic cells (pDCs) circulate in the blood and 
may home to lymphoid organs. They are capable of producing 
1000 times more type 1 IFN than any other cell type (121). TLR7, 
TLR9, and interferon regulatory factor 5 (IRF5) are constitu-
tively expressed by pDC (122). In 1982, Preble et  al. reported 
interferon-α activity in the serum of patients suffering from SLE 
(123). pDCs were identified as main producer of IFN-α when 
they encountered DNA-containing IC from sera of patients with 
SLE (124). Genetic susceptibility for SLE includes genes encoding 
(1) components of pathways upstream and downstream of type I 
IFN, such as components of TLR and IFN signaling pathways, (2) 
intracellular DNA degradation, and (3) autophagy-related genes, 
which might all foster IFN-α production by pDC (125). Using 
oligonucleotide microarrays, Baechler et  al. found that there is 
an overexpression of IFN-α induced genes in active SLE patients 
(126). During flares, ANAs encounter nucleic acid containing 
SNEC and undegraded NETs either in the circulation or deposited 
in tissues where they form IC. These tend to activate pDC and B 
cells. IC are internalized by pDCs via FcγRIIa and activate TLR9 
and TLR7, leading to secretion of the cytokines IFN-α and IL-6 
(127) (Figure 2). IFN-α induces the differentiation of autoreac-
tive B cells into plasmablasts, and these further differentiate into 
autoantibody-secreting plasma cell driven by IL-6.
As mentioned above, some lupus patients do not clear NETs 
sufficiently. DNase I inhibitors, anti-NET antibody, and deposi-
tion of C1q may be involved in the impaired clearance of NETs 
in lupus. Lande et al. have demonstrated that DNA/anti-DNA/
LL37 complexes circulate in the blood of some patients with SLE. 
These NET-derived complexes stimulate pDC to release IFN-α 
in a FcγRII- and TLR9-dependent manner (128). Garcia-Romo 
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et al. showed that mature neutrophils from SLE patients are prone 
to die as they significantly express TLR and IFN transcripts. IFN-
α and SLE serum enhances TLR7 expression in neutrophils. It 
has been shown that FcγRIIa, endosomal TLR7 signaling, and 
ROS formation are required for anti-ribonucleoprotein antibody-
induced SLE NETosis. SLE neutrophils secrete more LL-37 and 
HMGB-1 in the presence of anti-ribonucleoprotein antibodies, 
thereby increasing the immunogenicity of DNA. This contributes 
to the uptake of LL37-decorated chromatin by pDC and secre-
tion of high levels of IFN-α (129). In summary, the presence of 
anti-NET antibodies against DNA and low DNase activity foster 
the accumulation of uncleared NETs. These uncleared NETs are 
composed of DNA decorated with granular, modified proteins 
and anti-NET antibodies and serve as inducers of IFN-α by pDC. 
Hence, uncleared NETs can be a potential contributor to the IFN-
α signature in lupus (Figure 2).
Additionally, Manfredi et al. have shown that neutrophils that 
have phagocytosed apoptotic bodies lose their ability to respond 
to activating stimuli, such as IL-8, that induce NET generation. 
This shows that clearance deficiency of apoptotic cells may also 
enhance NETosis (130). This might contribute to the chronicity of 
inflammation and tissue injury observed in SLE. This novel link 
between impaired apoptotic cell clearance and NET generation 
provides a new aspect in the pathogenesis of both SLE and the 
ANCA-associated vasculitis (131).
CONCLUSiON
In summary, clearance deficiency participates in the breakdown 
of the tolerance to self, leading to the initiation of an autoimmune 
response mainly directed against nuclear autoantigens. Clearance 
deficiency also participates in the perpetuation of chronic inflam-
mation by providing autoantigens that trigger and enhance local 
inflammatory responses mediated by autoantibody. The clearance 
deficiency of apoptotic debris and the remnants of NET cumu-
latively leads to a challenge to self-tolerance and continually 
induces local and systemic inflammation in patients with SLE or 
vasculitis.
As a multifactorial disease, SLE has no single diagnostic 
marker, and the current diagnosis is based on clinical and labora-
tory criteria described by the American College of Rheumatology 
(ACR). The detection of ANA is the main primary laboratory test 
for SLE. According to ACR, a patient is classified as having SLE 
when high titers of ANA and other clinical criteria indicating two 
or more organ involvement are present (132). Tests for antibody 
to double-stranded DNA and antibody to Sm nuclear antigen 
and antiphospholipid antibody are performed when patients 
have an ANA antibody titer of 1:40 without any clinical criteria. 
Immunodiffusion, immunofluorescence, and ELISA are used to 
detect ANA (133). Rodent or human epithelial tissue (Hep2 cells), 
purified antigens or recombinant antigens are used as substrate to 
detect autoantibodies in SLE blood. These substrates have some 
limitations; for example, Hep-2 gives more insignificant positive 
results (133). When purified antigen is used, it may contain some 
contaminants or may not show all relevant epitopes. Hence, there 
is a need to have a diagnostic substrate that covers the repertoires 
of modified epitopes seen during apoptosis and NETosis.
In 1948, Hargraves et  al. reported “LE cell phenomenon” 
in bone marrow preparation of SLE patients (134). LE cell 
phenomenon is considered as the autoantibody-mediated 
phagocytosis of nuclear material by polymorphonuclear leuko-
cytes. Unfortunately, the LE cell preparation was ablated as a 
diagnostic tool for SLE in 1997 due to development of more 
simple methods to detect ANA activity. Nevertheless, the LE cell 
phenomenon provided fundamental evidence to understand the 
pathogenesis of SLE, namely the phagocytosis of nuclear material 
mediated by autoantibodies against modified autoantigens in a 
clearance deficiency scenario. Therefore, new diagnostic tools 
should be developed on the basis of this LE-cell phenomenon 
in order to get a closer in vivo picture of the clinicopathologic 
status of patients with SLE.
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